Program

Sunday 19 June 2016

14.00 — 20.00 Registration starts
16.00 — 16.20 Conference opening
Opening remarks Steven Cramer, Günter Jagschies, Phil Lester
16.20 — 18.00 Session 1: The Origin of Impurities
Session chairs: Ganesh Vedantham, Ashraf Amanullah
16.30 — 17.00 Sources of mAb Aggregate and Process Control Strategy
Min Zhu, MedImmune
17.00 — 17.30 Optimising cell design steps for efficient removal of E. coli host cell DNA impurities from Fab’ fragment process streams
Darren N. Nesbeth, University College London
17.30 — 18.00 Isolation and characterization of incompletely assembled bispecific antibody variants
Thomas von Hirschheydt, Roche
18.45 — 20.00 Welcome Reception and Opening Keynote
What is your blood? The circulating antibody repertoire in humans
George Georgiou, University of Texas
20.00 — 22.00 Opening Dinner

Monday 20 June 2016

08.00 — 10.05 Session 2: New Materials for Downstream Processing
Session chairs: Andrew Zydney, Michael Phillips
08.05 — 08.35 Evaluation of Next Generation Hybrid Filters for Simultaneous Clarification and Purification of Biologics
Nripen Singh BMS
08.35 — 09.05 3D-Printed Agarose Cation-Exchange Monoliths for Protein Capture from Solids-Laden Feeds
Conan Fee, University of Canterbury
09.05 — 09.35 Application of Smart Polymers in the Downstream Processing of Biological Products
Milton Hearn, Monash University
09.35 — 10.05 Novel ultrafiltration membranes produced by electrospinning
Mikhail Kozlov, MilliporeSigma
10.05 — 10.35 Morning Break
10.35 — 11.20 Keynote: Bioprocess Research and Practice in the Coming Age of Personalized Medicine
Charles Haynes, University of British Columbia
11.20 — 12.55 Session 3: The Marriage of HTS & Process Modelling
Session chairs: Marcel Ottens, Ernst Broberg Hansen
11.25 — 11.55 The Application of HTPD Datasets for Smarter Process and Molecular Design
Gregory Barker, BMS
11.55 — 12.25 Mechanistic Chromatography Modeling for Industrial Applications — A Lean Approach to a Complicated Tool
Chris Williams, Genentech
12.25 — 12.55 Experimental and computational lysate characterization for fast bioprocess optimization...
Pascal Baumann, KIT
12.55 Lunch break (boxlunch pick up and departure for activity afternoon)
13.25 Activity Afternoon
18.45 Dinner

20.00 — 22.00 Poster Session 1: An Ocean of Innovation
Session chairs: Charles Haynes, Abraham Lenhoff, David Roush

Tuesday 21 June 2016

08.00 — 10.05 Session 4: Impact from Alternative Expression Systems
Session chairs: Suzanne Farid, Lars Pampel
08.05 — 08.35 Alternate Reality: Alternate Expression Systems and the Future of Biomanufacturing
Matthew Westoby, Biogen
08.35 — 09.05 Lessons Learned from Developing a Platform Purification Approach for Domain Antibodies
Andre C. Dumetz, GSK
09.05 — 09.35 Purification of secretory IgA from Lemna minor (duckweed)
Michel Eppink, Synthon
09.35 — 10.05 Morning Break
10.05 — 10.50 Keynote: A Holistic Approach to Targeting Disease with Polymeric Nanoparticles
Mark Saltzman, Yale University
10.50 — 12.25 Session 5: Priorities in Cost & Performance Improvements
Session chairs: David Robbins, Sanchayita Ghose
10.55 — 11.25 A Downstream Approach for Maximizing Recoverable Titer and Facility Throughput
Amit Mehta, Genentech
11.25 — 11.55 GMP: Get the Most out of your Plant (by integrating unit operations)
Jace Fogle, Eli Lilly
11.55 — 12.25 Meeting Challenges in Productivity and Product Quality Improvements for the Manufacture of a Recombinant Enzyme
Michaela Wendeler, MedImmune
12.25 Lunch break
14.25 — 16.30 Session 6: Purification of non-Protein Therapeutics
Session chairs: Hari Pujar, Caryn Heldt
14.30 — 15.00 Improving washing strategies of human mesenchymal stem cells using negative mode expanded bed chromatography
Cristina Peixoto, IBET
15.00 — 15.30 Challenges in the Development and Scale-up of an Attenuated Live Virus Vaccine Candidate
Mark Wenger, Merck/GSK
15.30 — 16.00 Use of ultrafiltration for the purification of conjugated polysaccharide vaccines
Andrew Zydney, Penn State University
16.00 — 16.30 Re-designing purification processes for oligonucleotides; what’s achievable?
Robert Gronke, Biogen
16.30 Dine-around (Hotel Restaurants)
19.45 — 22.00 Debates Session I / II / III (in series)
Session chairs: Nigel Titchener Hooker, John Curling
19.50 — 20.30 Continuous Processing, where should we be operating?
Jonathan Coffman, Brian Kelley — Moderator: John Curling
20.30 — 21.10 Disruptive Technologies, why do they not seem to stick?
Hanne Bak, Jörg Thömmes — Moderator: Todd Przybycien
21.10 — 21.50 Design of Experiments versus Modelling, show me the value!
Karol Łački, Jürgen Hubbuch — Moderator: Arne Staby
21.50 — 22.00 Debate closing
Moderators

Wednesday 22 June 2016

08.00 — 10.05 Session 7: Purification from Platform to Diversity
Session chairs: Nihal Tugcu, Dorothee Ambrosius
08.05 — 08.35  Modular approaches for diverse molecules: reinventing smart bioprocessing
  Stefan Schmidt, Rentschler

08.35 — 09.05  Leveraging HTPD to streamline implementation of non-platform therapeutics to minimize impact to development timelines
  Jennifer Pollard, Merck

09.05 — 09.35  Evolution of a Standard Downstream Purification Process for Knob-in-Hole Bispecific Antibodies
  Asif Ladiwala, Genentech

09.35 — 10.05  A μl-scale process representing the entire upstream and downstream processing chain
  Cornelia Walther, BOKU

Molecular properties perspective in the development of chromatographic strategies for Bispecific Antibodies
  Tiago Matos, Novo Nordisk

10.05 — 10.35 Morning break

10.35 — 11.20  Keynote: The Future of Biomanufacturing
  Jörg Thömmes, Biogen

11.20 — 12.55  Session 8: Process Challenges with Biosimilars
  Session chairs: Suresh Vunnum, Jill Myers

11.25 — 11.55  Transforming Cancer Care: Affordable and Accessible Biosimilars
  Steven Lehrer, Cipla BioTec

11.55 — 12.25  Challenges and approaches in the development of a biosimilar purification process
  Russell Shpritzer, Pfizer

12.25 — 12.55  Advances and Challenges in the Analytical Characterization of Biosimilar Products
  Jeff Allen, Pfenex

12.55  Lunch break (boxlunch pick up and departure for activity afternoon)
13.25  Activity Afternoon
18.45  Dinner
20.00 — 22.00  Poster Session 2: An Ocean of Innovation
  Session chairs: Charles Haynes, Abraham Lenhoff, David Roush

Thursday 23 June 2016
08.00 — 10.05  Session 9: Next Generation Unit Operations & Integrated Processes
  Session chairs: Jeff Salm, John Moscariello

08.05 — 08.35  Perturbations of steady states in continuous bioprocessing
  Mark Brower, Merck

08.35 — 09.05  A Multi-Stage Hybrid Integrated System for Downstream Processing of Monoclonal Antibodies from a Continuous Perfusion Bioreactor
  Rob Fahrner, Pfizer

09.05 — 09.35  Alternative Downstream Processing based on Continuous Coupled Precipitation-Filtration Capture Operations
  Todd Przybycien, Carnegie Mellon Univ

09.35 — 10.05  Implementation of an End-to-End Continuous BioProcessing Platform using Novel Technologies
  Engin Ayturk, Pall

10.05 — 10.35 Morning break

10.35 — 11.20  Keynote: Trends in the global burden of disease: early results from the Global Burden of Disease 2015 study and forecasts to 2040
  Christopher Murray, Institute for Health Metrics and Evaluation

11.20 — 12.55  Session 10: Biomolecular Modelling for Manufacturability
  Session chairs: Christopher Dowd, Peter Tessier

11.25 — 11.55  Synthesis of Computational and Experimental Developability to
11.55 — 12.25 Molecular Basis of Strong Association in Monoclonal Antibodies: Atomistic Computations and Small-Angle Scattering
Abraham Lenhoff, Univ. of Delaware

12.25 — 12.55 Mechanistic model of excipient exchange during protein formulation by UF/DF
Roger A. Hart, Amgen

12.55 Lunch break

14.15 — 15.00 Session 11: New Developments in PAT and QbD
Session chairs: Gisela Ferreira, Thorsten Lemm
14.20 — 14.50 From first principles chromatography modeling to process control strategy
Cenk Undey, Amgen
Gunnar Malmquist, GE Healthcare and Canping Jiang, Biogen
15.20 — 15.50 Raman spectroscopy-based multivariate analysis as a PAT tool for impurity detection and adaptive process control in DSP
Siddharth Parimal, Biogen

15.50 — 16.20 Afternoon Break

16.20 — 17.55 Session 12: Increasing Patient Access to Biopharmaceuticals
Session chairs: Jon Coffman, Bruno Marques
Joseph Shultz, Novartis
16.55 — 17.25 A Simple GPS for Lowering Capital Cost, Which Is Too High, Even With High Margins
John Erickson, GSK
17.25 — 17.55 Manufacturing gp120 based novel HIV vaccine candidates: simultaneously meeting the demands of cost and rapid progression from bench to bedside
Abhinav Shukla, KBI Biopharma

20.00 — 22.00 Closing Dinner & New Chairs: Announcement